PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33729906-6 2021 In this study, we described the chemical synthesis, in vitro drug release and antiproliferative activity of doxorubicin-loaded/decorated MSNs further coupled with FA in two conditions: chemically bound or as a complex with CM-beta-CD. Doxorubicin 108-119 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 226-233 33862128-2 2021 Along with its excellent biocompatibility, the prepared HA-beta-CD exhibits not only exceptionally high loading capacity for the model drugs doxorubicin and Rhodamine B through the formation of inclusion complexes with the beta-CD component, but also the capability of targeted drug delivery to cancerous cells with a high level of expression of CD44 receptors, attributable to its HA component. Doxorubicin 141-152 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 59-66 33862128-2 2021 Along with its excellent biocompatibility, the prepared HA-beta-CD exhibits not only exceptionally high loading capacity for the model drugs doxorubicin and Rhodamine B through the formation of inclusion complexes with the beta-CD component, but also the capability of targeted drug delivery to cancerous cells with a high level of expression of CD44 receptors, attributable to its HA component. Doxorubicin 141-152 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 223-230 33035717-2 2021 Herein, we proposed a kind of heparanase (HPSE)-driven sequential released nanoparticles, which modified with beta-cyclodextrin (beta-CD) grafted heparin (NLC/H(D + F + S) NPs) co-loading with doxorubicin (DOX), ferrocene (Fc), and TGF-beta receptor inhibitor (SB431542). Doxorubicin 193-204 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 129-136 33383572-3 2021 The hydrophobic anticancer drug doxorubicin (Dox) was encapsulated inside the hydrophobic core of bis(beta-CD) via hydrophobic association with loading capacity of 24 % in weight and a hydrodynamic size of about 100 nm. Doxorubicin 32-43 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 102-109 33383572-3 2021 The hydrophobic anticancer drug doxorubicin (Dox) was encapsulated inside the hydrophobic core of bis(beta-CD) via hydrophobic association with loading capacity of 24 % in weight and a hydrodynamic size of about 100 nm. Doxorubicin 45-48 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 102-109 33035717-2 2021 Herein, we proposed a kind of heparanase (HPSE)-driven sequential released nanoparticles, which modified with beta-cyclodextrin (beta-CD) grafted heparin (NLC/H(D + F + S) NPs) co-loading with doxorubicin (DOX), ferrocene (Fc), and TGF-beta receptor inhibitor (SB431542). Doxorubicin 206-209 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 129-136 32747290-8 2020 DOX@GQDs-PAMAM-beta-CD displayed the pH-sensitive drug release profile, which fitted the Higuchi kinetic model. Doxorubicin 0-3 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 15-22 32922527-1 2020 This article reports a novel thiolated beta-cyclodextrin (HS-beta-CD) modified nanoporous gold (NPG) wire for pH sensitive delivery of doxorubicin (DOX) in controlled manner. Doxorubicin 135-146 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 61-68 32922527-1 2020 This article reports a novel thiolated beta-cyclodextrin (HS-beta-CD) modified nanoporous gold (NPG) wire for pH sensitive delivery of doxorubicin (DOX) in controlled manner. Doxorubicin 148-151 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 61-68 32922527-3 2020 HS-beta-CD can form supramolecular inclusion complexes with DOX affording the possibility of altering the controlled release behavior. Doxorubicin 60-63 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 3-10 32420760-4 2020 The stepwise physicochemical changes for the preparation of the DOX loaded 5-ALA-CQD-Glu-beta-CD system were investigated by Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), transmission electron microscopy (TEM), atomic force microscopy (AFM), and Raman fluorescence spectroscopy. Doxorubicin 64-67 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 89-96 32420760-5 2020 The encapsulation efficiency of DOX in 5-ALA-CQD-Glu-beta-CD was observed at ~83.0%, and the loading capacity of DOX is ~20.37%. Doxorubicin 32-35 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 53-60 32420760-7 2020 By the investigation against the breast MCF-7 cancer cells, the high cytotoxicity and morphological changes of cancer cells were observed by the treating of DOX/5-ALA-CQD-Glu-beta-CD. Doxorubicin 157-160 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 175-182 32420760-9 2020 In vitro cellular uptake studies recommend the synthesized DOX/5-ALA-CQD-Glu-beta-CD nanocarrier could significantly enhance the cell apoptosis and assist in the MCF-7 cell damages. Doxorubicin 59-62 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 77-84 32747290-10 2020 Moreover, DOX@GQDs-PAMAM-beta-CD exhibited more efficiency in the killing of the cancer cells compared to neat DOX. Doxorubicin 10-13 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 25-32 32747290-10 2020 Moreover, DOX@GQDs-PAMAM-beta-CD exhibited more efficiency in the killing of the cancer cells compared to neat DOX. Doxorubicin 111-114 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 25-32 32823816-3 2020 Here, we demonstrated that the combination of alphaCD and betaCD enabled to load and control release of two anticancer drugs: doxorubicin (DOX) and beta-lapachone (beta-LP) (DOX in beta-CD and beta-LP into alpha-CD) via host-guest inclusion. Doxorubicin 126-137 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 206-214 31403158-4 2019 In this study, a novel derivative of beta-cyclodextrin (beta-CD), glutamine-beta-cyclodextrin (GLN-CD), was developed by conjugating glutamine with the 6-hydroxy of beta-CD, and GLN-CD was then used to prepare doxorubicin (DOX) inclusion complexes (DOX@GLN-CD) for TNBC treatment. Doxorubicin 210-221 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 56-63 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 101-104 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 37-44 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 101-104 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 88-95 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 155-166 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 37-44 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 155-166 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 88-95 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 150-153 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 37-44 31541178-2 2019 The spherical micelles was formed by beta-CD-DPPE molecule in aqueous solution, and the beta-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 +- 7.27%. Doxorubicin 150-153 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 88-95 31541178-4 2019 Biological test showed that the micelles was low cytotoxicity, and the cytotoxicity of beta-CD-DPPE-Dox nanomedicine was lower than the Dox under the same Dox concentration, and the beta-CD-DPPE-Dox nanomedicine could effectively induce cancer cell apoptosis and inhibit the tumor growth. Doxorubicin 100-103 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 87-94 31541178-4 2019 Biological test showed that the micelles was low cytotoxicity, and the cytotoxicity of beta-CD-DPPE-Dox nanomedicine was lower than the Dox under the same Dox concentration, and the beta-CD-DPPE-Dox nanomedicine could effectively induce cancer cell apoptosis and inhibit the tumor growth. Doxorubicin 100-103 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 182-189 31403158-4 2019 In this study, a novel derivative of beta-cyclodextrin (beta-CD), glutamine-beta-cyclodextrin (GLN-CD), was developed by conjugating glutamine with the 6-hydroxy of beta-CD, and GLN-CD was then used to prepare doxorubicin (DOX) inclusion complexes (DOX@GLN-CD) for TNBC treatment. Doxorubicin 223-226 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 56-63 31403158-4 2019 In this study, a novel derivative of beta-cyclodextrin (beta-CD), glutamine-beta-cyclodextrin (GLN-CD), was developed by conjugating glutamine with the 6-hydroxy of beta-CD, and GLN-CD was then used to prepare doxorubicin (DOX) inclusion complexes (DOX@GLN-CD) for TNBC treatment. Doxorubicin 249-252 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 56-63 31403158-11 2019 As a novel derivative of beta-CD, GLN-CD is an effective carrier that can specifically deliver DOX to TNBC cells via targeting ASCT2 and minimize its uptake by normal cells. Doxorubicin 95-98 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 25-32 27064666-1 2016 PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%-20%) for febrile neutropenia (FN) in breast cancer. Doxorubicin 9-20 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 74-78 35044605-1 2022 The purpose of this investigation was to analyze the performance of magnetite graphene oxide modified with beta-cyclodextrin (GO@Fe3O4@beta-CD) for adsorption of methotrexate (MTX) and doxorubicin (DOX) from aqueous solutions. Doxorubicin 185-196 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 135-142 35044605-1 2022 The purpose of this investigation was to analyze the performance of magnetite graphene oxide modified with beta-cyclodextrin (GO@Fe3O4@beta-CD) for adsorption of methotrexate (MTX) and doxorubicin (DOX) from aqueous solutions. Doxorubicin 198-201 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 135-142 35044605-4 2022 The adsorption kinetic of MTX and DOX via GO@Fe3O4@beta-CD followed pseudo second-order (PSO) model, while the adsorption isotherm obeyed Langmuir model by monolayer adsorption with maximum adsorption capacities of 198.5 and 204.5 mg g-1 for MTX and DOX, respectively. Doxorubicin 34-37 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 51-58 35044605-4 2022 The adsorption kinetic of MTX and DOX via GO@Fe3O4@beta-CD followed pseudo second-order (PSO) model, while the adsorption isotherm obeyed Langmuir model by monolayer adsorption with maximum adsorption capacities of 198.5 and 204.5 mg g-1 for MTX and DOX, respectively. Doxorubicin 250-253 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 51-58